Senior or Junior Organic Chemists required for our newly established R&D facility in Copenhagen, Denmark.
Help us transform chemical synthesis to become sustainable.
The global challenge
Using current state-of-the-art batch manufacturing, an estimated 4000 kg of toxic solvents is consumed to manufacture 1 kg peptide, generating the same amount of hazardous waste – this is not sustainable!
Solid Phase Peptide Synthesis (SPPS) was a major disruption peptide chemistry when Nobel laureate Robert Bruce Merrifield first introduced this in 1963 enabling synthesis of long peptides at industrial scale. It is becoming more and more evident that future manufacturing processes are environmentally sustainable; however, no development has seen the light of day since then despite the great need for innovation. An estimated 4000 kg of toxic solvents is consumed when manufacturing 1 kg of a 30 amino acid peptide, generating the same amount of hazardous waste.
The µLOT® technology
The μLOT® technology makes it possible to produce peptides in a sustainable manner – as never before.
The μLOT® system is the first major breaktrhough since the invention of SPPS enabling true end-to-end continuous synthesis of peptides in large scale for the pharmaceutical industry revolutionising peptide manufacturing.
The keyword is sustainability and we are aiming at a >100 fold reduction in the consumption of toxic solvents and generation of hazardous waste by harnessing:
- Continuous synthesis and counter flow chemistry
- Full control of all process parameters
- Full control of product quality using in-line analytics (PAT), multi variate statistics and quality by design (QbD)
The job role
SB3000 are looking for keen and dynamic people to support the development of the technology and equipment. The role will focus on leading and conducting the chemistry work for not only inhouse development activities but also clients. The team are very inclusive and look for input to the development and running of activities from all parties.
The responsibilities. Together with our management team and our team of highly skilled engineers, you will establish our new wet lab facility including recruitment of scientists and technicians to build a strong chemistry and analytical group in Lyngby and most importantly, you will be operational in the lab. The facility in Lyngby has three main responsibilities; 1) supporting our current and future collaborators in the pharmaceutical industry, and; 2) develop new and sustainable chemistry applications for the µLOT® technology and; 3) supporting the development and commercialisation of the µLOT®.
The opportunities. The positon offers a competitive package and the opportunity to be part of something big! The positive environmental impact of implementing the µLOT® technology throughout pharmaceutical manufacturing is beyond imagination and you will play a critical role in making this happen. Together we will develop and enable the technology for multiple applications starting with true end-to-end continuous peptide synthesis in industrial scale.
- MSc or PhD with a deep scientific understanding of organic chemistry
- A sound curiosity and an Innovative and open mindset
- Experience from pharmaceutical development, discovery, pilot plant or a commercial facility
- Diligent practice in documenting your work
- Solid phase synthesis of peptides, carbohydrates or oligo nucleotides
- Continuous manufacturing, flow or counter flow chemistry
- Hands on approach to working with new development equipment (technical awareness).
Applying for the role
If you are a team player that poses a handful of the listed competencies and the drive to be part of something big, please submit your CV/resume to Executive Assistant Claire Adcock (firstname.lastname@example.org) marking your application “Organic chemist” in the subject field.
Any questions – please contact Jens Bukrinski, Head of R&D, email: Jens@SB3000.tech or mobile: +45 29 62 42 62.
We plan to start interviews in the week stating July 20th, 2020.
The company – SB 3000.
SB 3000 was founded by Lars Uno-Larsson (recipient of the Honorary Award for Visionary and Pioneering Guidance in the Orphan Drug area) and have developed the innovative μLOT® technology by mimicking natures approach to complex biological or chemical challenges.
We are a small team of highly competent employees dedicated to make the µLOT technology ready for commercialisation, based in Hethel, UK and now establishing our wet lab facilities in Lyngby, DK.
We are committed to contribute significantly to the fulfilment of the UN-sustainability goals.